Tafetinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Tafetinib (SIM010603) 是一种口服多靶点酪氨酸激酶受体抑制剂。Tafetinib 抑制干细胞因子受体(Kit)、血管内皮生长因子受体-2 (VEGFR-2)、血小板来源的生长因子受体-β (PDGFR-β)、胶质细胞系来源的神经营养因子受体(转染时重排;RET)和 fms 样酪氨酸激酶3 (FLT3)，其 IC50 值在 5.0 ~ 68.1 nmol/l之间。Tafetinib 抑制 PDGFR-β 和 VEGFR-2 的磷酸化。Tafetinib 抑制内皮细胞增殖、内皮细胞趋化和角膜血管生成。

Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.

——

——

——

Proteasome/Ubiquitin

Tyrosinase

Tyrosine Kinases

——

——

1032265-57-8

424.51

C24H29FN4O2

>98% (HPLC)

——

O=C1/C(=C/2\C3=C(C(C(NCCN(CC)CC)=O)=C(C)N3)CCC2)/C=4C(N1)=CC=C(F)C4

——

(-20℃)

With Ice Pack

≥ 2 years